[4-(三氟甲基)-1,3-噻唑-2-基]氨基甲酸苯酯 | 625119-98-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [4-(三氟甲基)-1,3-噻唑-2-基]氨基甲酸苯酯
• 英文名称: phenyl N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]carbamate
• 英文别名: phenyl [4-(trifluoromethyl)-1,3-thiazol-2-yl]carbamate；phenyl 4-(trifluoromethyl)-1,3-thiazol-2-yl-carbamate
• CAS: 625119-98-4
• 化学式: C₁₁H₇F₃N₂O₂S
• 分子量: 288.25
• InChiKey: WOIUNWZQHLGDMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [4-(三氟甲基)-1,3-噻唑-2-基]氨基甲酸苯酯 、 2-甲基-3-氨基苯酚 在 氨 作用下， 以 甲醇 、 水 为溶剂， 反应 0.33h， 以67%的产率得到N-(3-hydroxy-2-methylphenyl)-N'-[4-(trifluoromethyl)-1,3-thiazol-2-yl]urea
  参考文献：
  名称：

  Positive allosteric modulators of the nicotinic acetylcholine receptor

  摘要：

  这项发明提供了I式化合物： 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对治疗已知涉及α7 nAChR的疾病或症状的药物非常有用。

  公开号：

  US20030236287A1
• 作为产物：
  描述：

  2-氨基-4-三氟甲基噻唑 、 氯甲酸苯酯 在 吡啶 、 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 以65%的产率得到[4-(三氟甲基)-1,3-噻唑-2-基]氨基甲酸苯酯
  参考文献：
  名称：

  Positive allosteric modulators of the nicotinic acetylcholine receptor

  摘要：

  这项发明提供了I式化合物： 这些化合物可以是药用盐或组合物的形式，可以是纯对映体形式或混合物，对治疗已知涉及α7 nAChR的疾病或症状的药物非常有用。

  公开号：

  US20030236287A1

文献信息

• [EN] SPIROCYCLIC PIPERIDINE DERIVATIVES AS TRPM 8 MODULATORS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE SPIROCYCLIQUES EN TANT QUE MODULATEURS DE TRPM8
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2010103381A1

  公开（公告）日：2010-09-16

  The present invention provides Transient Receptor Potential subfamily M, member 8 (TRPM8) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPM8. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPM8.

  本发明提供了公式（I）的瞬时受体电位亚家族M，成员8（TRPM8）调节剂。特别地，本文所描述的化合物对于治疗或预防TRPM8调节的疾病，状况和/或紊乱非常有用。本文还提供了制备所述化合物的过程，用于其合成的中间体，其制药组合物以及用于治疗或预防由TRPM8调节的疾病，状况和/或紊乱的方法。
• Heterocyclic Compounds as Ccr2b antagonists
  申请人：Bower Justin Fairfield

  公开号：US20090099156A1

  公开（公告）日：2009-04-16

  Compounds of formula (I) Q-L-W—C(═X)-Z-P wherein Q is an amine of the formula —N(R 1 )(R 2 ); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 which are linked to groups L and C(X) respectively and Y 1 and Y 2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR 3 ; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.

  化合物的公式（I）Q-L-W—C（═X）-Z-P，其中Q是公式—N（R1）（R2）的胺基；L是烷基或杂环基烷基连接物；W是由环原子Y1和Y2组成的6-或7-成员脂肪环，其中Y1和Y2分别与基团L和C（X）连接，并且Y1和Y2分别独立地从N和C中选出；X是O、N、N—CN或S；Z是NR3；P是可选取代的单环或双环芳基或杂芳基基团；以及其药学上可接受的盐或溶剂，可用于治疗C-C趋化因子介导的疾病。
• Heterocyclic Compounds as CCR2 Antagonists
  申请人：Bower Justin Fairfield

  公开号：US20120264762A1

  公开（公告）日：2012-10-18

  Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R 1 )(R 2 ); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 which are linked to groups L and C(X) respectively and Y 1 and Y 2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR 3 ; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.

  化合物的式子为(I)Q-L-W—C(═X)—Z—P，其中Q是公式—N(R1)(R2)的胺基；L是烷基或杂环烷基-烷基连接物；W是一个6-或7-成员的脂肪环，包括环原子Y1和Y2，它们分别与基团L和C(X)相连，Y1和Y2独立地选自N和C；X是O、N、N—CN或S；Z是NR3；P是一个可选择取代的单环或双环芳基或杂芳基基团；以及其药学上可接受的盐或溶剂，用于治疗C-C趋化因子介导的疾病。
• HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS
  申请人：AstraZeneca AB

  公开号：US20140038978A1

  公开（公告）日：2014-02-06

  Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R 1 )(R 2 ); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 which are linked to groups L and C(X) respectively and Y 1 and Y 2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR 3 ; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.

  化合物的公式为(I)Q-L-W—C(═X)—Z—P，其中Q是公式—N(R1)(R2)的胺基；L是烷基或杂环烷基-烷基连接物；W是一个6-或7-成员的脂肪环，包括环原子Y1和Y2，它们分别与基团L和C(X)连接，并且Y1和Y2独立地选自N和C；X是O、N、N—CN或S；Z是NR3；P是可选取代的单环或双环芳基或杂芳基；以及其药学上可接受的盐或溶剂，用于治疗C-C趋化因子介导的疾病。
• Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1′H-spiro[chromene-2,4′-piperidine]-1′-carboxamides as TRPM8 antagonists
  作者：Sachin S. Chaudhari、Ashok B. Kadam、Neelima Khairatkar-Joshi、Indranil Mukhopadhyay、Pallavi V. Karnik、Anupindi Raghuram、Shobha S. Rao、Thamil Selvan Vaiyapuri、Dinesh P. Wale、Vikram M. Bhosale、Girish S. Gudi、Ramchandra R. Sangana、Abraham Thomas

  DOI：10.1016/j.bmc.2013.08.031

  日期：2013.11

  A novel series of N-aryl-3,4-dihydro-1'H-spiro[chromene-2,4'-piperidine]-1'-carboxamides was identified as transient receptor potential melastatin 8 (TRPM8) channel blockers through analogue-based rational design, synthesis and screening. Details of the synthesis, effect of aryl groups and their substituents on in-vitro potency were studied. The effects of selected functional groups on the 4-position of the chromene ring were also studied, which showed interesting results. The 4-hydroxy derivatives showed excellent potency and selectivity. Optical resolution and screening of alcohols revealed that (R)-(-)-isomers were in general more potent than the corresponding (S)-(+)-isomers. The isomer (R)-(-)-10e (IC50: 8.9 nM) showed a good pharmacokinetic profile upon oral dosing at 10 mg/kg in Sprague-Dawley (SD) rats. The compound (R)-(-)-10e also showed excellent efficacy in relevant rodent models of neuropathic pain. (C) 2013 Elsevier Ltd. All rights reserved.